Analyzing R&D Budgets: Sanofi vs Corcept Therapeutics Incorporated

Sanofi vs Corcept: A Decade of R&D Investment

__timestampCorcept Therapeutics IncorporatedSanofi
Wednesday, January 1, 2014183720004667000000
Thursday, January 1, 2015154190005082000000
Friday, January 1, 2016238440005232000000
Sunday, January 1, 2017403760005567000000
Monday, January 1, 2018752470006350000000
Tuesday, January 1, 2019890170006018000000
Wednesday, January 1, 20201147640005529000000
Friday, January 1, 20211138640005692000000
Saturday, January 1, 20221309910006706000000
Sunday, January 1, 20231843530006728000000
Monday, January 1, 20247394000000
Loading chart...

Unleashing the power of data

Analyzing R&D Budgets: Sanofi vs Corcept Therapeutics

In the ever-evolving pharmaceutical landscape, research and development (R&D) budgets are pivotal in driving innovation. This analysis compares the R&D expenditures of two industry players: Sanofi, a global healthcare leader, and Corcept Therapeutics, a niche biopharmaceutical company. From 2014 to 2023, Sanofi consistently invested significantly more in R&D, with expenditures peaking at approximately $6.7 billion in 2023. In contrast, Corcept Therapeutics, while smaller in scale, demonstrated a remarkable growth trajectory, increasing its R&D spending by nearly tenfold over the same period, from $18 million in 2014 to $184 million in 2023. This stark contrast highlights the differing scales and strategies of these companies. Sanofi's robust R&D budget underscores its commitment to maintaining a competitive edge, while Corcept's rapid growth reflects its strategic focus on innovation within its specialized field.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025